Kornimate/medical-research-clean huggingface dataset:
impact of the inspiratory cortical control on the outcome of the ventilatory weaning test in patients intubated in resuscitation

Conditions: Respiration Disorder; Respiratory Failure; Weaning Failure; Respiratory Compensation; Respiratory Center Dysfunction

Summary: in case of respiratory distress, patients are intubated to be connected to an artificial respirator to ensure gas exchanges. before any ventilatory weaning, a breathing test in spontaneous ventilation under artificial nose is practiced. the patient keeps the endotracheal tube but is no longer assisted by the ventilator. mortality is markedly increased with the prolongation of the weaning period. despite the presence of all weaning criteria and the success of a breathing test in spontaneous ventilation under artificial nose, failure of extubation occurs in 20% of patients. experimental application of an additional inspiratory load in awake healthy subjects causes a compensatory increase in respiratory work to maintain effective ventilation, and the subject does not develop hypoventilation. this respiratory drive to breathe has been demonstrated by quantified electroencephalography in inspiratory load tests in the form of pre-inspiratory negative deflections of low amplitude similar to the potential described during the preparation of the voluntary movement of a limb. these inspiratory pre-motor potentials begin about 2.5 seconds before the start of a movement in the additional motor area. does the simple and noninvasive analysis of inspiratory cortical control during the spontaneous ventilation breath test under artificial nose predict the outcome of this test as well as weaning at 7 days?


Eligibility criteria:
inclusion criteria: * all intubated-ventilated patients eligible for an artificial nose breathing test in spontaneous ventilation, according to the physician in charge, and to the protocol of the medical resuscitation service and good clinical practice, * at least 18 years of age; * intubated-ventilated for at least 24 hours; * express consent given by patients or "relatives" after clear and fair information on the study. exclusion criteria: * patients are secondarily excluded from the study only if eeg or pressure monitoring are uninterpretable.
specialized proresolving mediators in pneumocystis jirovecii pneumonia

Conditions: Pneumonia, Pneumocystis

Summary: this study aims to evaluate specialized proresolving mediators (spm) concentrations for the first time in subjects infected with pneumocystis jirovecii. spm will be measured in blood and urine in patients with favourable or unfavourable outcome of pneumocystis pneumonia and in patients colonized by pneumocystis jirovecii. the hypothesis is that low levels of spm in the blood could be predictive of a negative outcome of pneumocystosis.

pneumocystis pneumonia is a severe fungal disease threatening immunosuppressed subjects such as patients suffering from aids, oncohematological diseases or solid organ transplanted patients. the disease is characterized by an important inflammation in the infected lungs which is mainly responsible for lungs lesions. despite an adequate treatment introduction, mortality is still around 20% which can not be explained by a treatment resistance. specialized proresolving mediators (spm), including lipoxins, maresins, protectins and resolvins, are newly described molecules implicated in the active process of inflammation resolution. the investigators hypothesis in this study is that high levels of spm could be predictive of a good resolution of the harmful inflammation, thus a good evolution of the disease, in adequate pneumocystosis therapy conditions. on the contrary, low levels of spm could be predictive of an unfavourable outcome despite a treatment targeting pneumocystis jirovecii

Eligibility criteria:
inclusion criteria: * patient over 18 years old * patient with a social security cover. * free and informed oral consent given. * pneumocystis infection or colonization diagnosed on bal (broncho-alveolar liquid) or sputum at toulouse university hospital mycology laboratory. * adequate pneumocystis therapy for infected patients (cotrimoxazole). exclusion criteria: * individuals placed under juridical protection, * individuals placed under guardianship, or supervision. * pregnancy or breastfeeding.

Keywords: pneumocystis jirovecii pneumonia specialized proresolving mediators inflammation prognosis
descriptive study regarding ambulant screening during covid-19 pandemia

Conditions: COVID 19

Summary: descriptive prospective study to investigate the prevalence of covid 19 during ambulant screening

the exact prevalence of covid-19 is unknown. due to the relatively high number of diagnosed, symptomatic infections despite a strict policy, we expect a high prevalence of covid 19 throughout the entire population. the risk that an asymptomatic carrier who is admitted to the hospital for a (semi)urgent surgery, treatment of investigation transfers the virus to the hospital staff is very high, and vice versa. this risk is even higher during surgery, where intubation is necessary. therefore we would like to pre-screen all patients ambulantly on the presence of covid 19 since there is no consensus for screening at the moment. the golden standard is the sars cov-2 pcr on the nasopharyngeal sample together with a ct scan of the lungs. patients in which a bloodsample is taken as standard of care procedure in this ambulant screening will be asked to give more blood for further investigation. on top of this standard of care screening, we will perform a questionnaire at the pre-operative visit which evaluates the possible occurence of certain symptoms in the last 2 weeks. these symptoms are fever, anorexia, cough, diarrhea, sneezing, vomiting, dyspnea, headache, rhinorrhea, loss of smell, muscle pain, sputum, sore throat and fatigue. patients were also asked if one of their housemates are affected by these symptoms. furthermore, 2 weeks after surgery, patient will be contacted to phone in order to fill the same questionnaire.

Eligibility criteria:
inclusion criteria: * all adult patients \> 18 years scheduled for a (semi) urgent surgery, hematological or oncological treatment or elektrophysiciological investigations in the jessa hospital exclusion criteria: * patients \< 18 years * adult patients who are unable the give informed consent * language barrier
effectiveness of eswt and pnf in scleroderma with calcinosis

Conditions: Scleroderma; Calcinosis Cutis

Summary: investigation of the effects of eswt and pnf exercises added to eswt on calcinosis in ssc patients. calcinosis cutis is a common, difficult-to-treat manifestation of systemic sclerosis associated with high morbidity. the aim of this study is to investigate the efficacy of eswt therapy for calcinosis cutis in ssc patients. the effects on grip strength, sleep, function and quality of life will be investigated.

in ssc patients, eswt and pnf exercises that they take to eswt should not be taken on calcinosis. calcinosis cutis is a common, difficult-to-treat manifestation of disseminated systemic sclerosis with high morbidity. the effects on machine power, sleep, function and quality of life will be investigated. evaluation methods - treatment rom (with goniometer), second force (dynamometer), ultrasound (evaluation of calcinosis size), dash (evaluation of ability to maintain upper extremity activities) , hamis (hand function test patient-specific functions assessment), pitsburgh sleep quality index (puki) - (sleep assessment assessment), pain assessment (with vas), health assessment questionnaire (shaq) (health status assessment) will be evaluated. as a result of the evaluation, two groups will be separated and one group will be eswt, one group will be applied pnf stretching in addition to ewst. treatment pnf tension : 10 sec against max resistance. the time will be done with isometric contraction. 5 sec. it will wait for active circuit. 8-10 will be repeated. 10 seconds between applications. listening range will be left. pnf will be applied 3 times a week, once a week. eswt: eswt will be applied 3 times in total, 20 minutes once a week. 2000 impulses will be applied on calcinosis. the patients will do the taught pnf exercises once a day as a home program. h1: pnf stretching exercises go on calcinosis when ssc patients go to eswt and eswt. h2: eswt and decreased to eswt in ssc patients pnf stretching exercises were not effective on calcinosis.

Eligibility criteria:
inclusion criteria: * being diagnosed with ssc according to acr/eular 2013 criteria * being diagnosed with calcinosis by a physician * have the ability to adapt to exercises * stability of medical treatments exclusion criteria: * being diagnosed with a known additional rheumatological or chronic disease * having a deformity that prevents doing the exercises * cognitive impairment * being pregnant

Keywords: scleroderma eswt pnf techniques
high intensity interval training in osteoarthritis, effects on metabolomics

Conditions: Knee Osteoarthritis

Summary: purpose: the purpose of this study will be to examine the feasibility and acceptability of a 6-week high intensity interval training (hiit) program in patients with knee oa symptoms ranging from mild to severe. a secondary purpose will be to evaluated changes in whole body metabolism induced by 6-weeks of hiit. participants: fifteen patients (age 40-70 yrs; bmi 20-35 kg/m²) with symptomatic knee oa procedures (methods): all participants will be assigned to the single-arm of the study in which all participants will receive 6 weeks of hiit, delivered twice per week. outcomes will be assessed at baseline and 6 weeks. the primary outcome will evaluate tolerability, feasibility, acceptability, compliance, and adherence to the hiit program. secondary outcomes will include whole body metabolism markers, inflammation, and a set of physical function including knee osteoarthritis symptomatic burden and pain, cardiorespiratory fitness, isometric knee extensor and flexor strength (factors associated with physical function and symptomatic knee oa progression), and body composition.


Eligibility criteria:
inclusion criteria: * must exhibit symptomatic knee oa (womac \> 31), radiographic evidence of tibiofemoral oa (2-4 kellgren-lawrence scale) * age 40-70 years * body mass index 20-35 kg/m² * cleared by study physician from 12 lead ekg and medical history review exclusion criteria: * individuals diagnosed with a cardiovascular condition restricting exercise individuals currently meeting department of health and human services guidelines for physical activity (meeting \>150 minutes of exercise per week) * individuals currently doing hiit * individuals currently participating in physical therapy for knee oa * individuals currently participating in another oa intervention study * received a corticosteroid or hyaluronic acid injection involved in the knee in the previous 3 weeks or scheduled for during the intervention * diagnosis of gout in the knee * diagnosis of rheumatoid arthritis * diagnosis of fibromyalgia * other systemic rheumatic disease * severe dementia or other memory loss * active diagnosis of psychosis or uncontrolled substance abuse disorder * hospitalization for a stroke, heart attack, or heart failure, or had surgery for blocked arteries in the past 6 months * diabetics (medications include exogenous insulin) * total joint replacement knee surgery, other knee surgery, meniscus tear, or acl tear in the past 12 months * on a waiting list for total joint replacement * severely impaired hearing or speech * pregnant or planning to become pregnant in the next 8 weeks * inability to speak english * serious or terminal illness as indicated by referral to hospice or palliative care * nursing home residence * inability to ride a stationary bike * any other health problems that would prohibit safe participation in the study.
enhanced external counterpulsation in patients with fontan circulation

Conditions: Single-ventricle; Congenital Heart Disease

Summary: the purpose of the proposed study is to determine the safety of enhanced external counterpulsation (eecp), a system for compressing the blood vessels in the legs in synchrony with an individual's cardiac rhythm, in clinically well, adult fontan patients, to document the acute hemodynamic and myocardial effects of eecp on the fontan circulation, and to demonstrate acute changes in endothelial function after one hour of the procedure.

the investigators plan to study the effects of enhanced external counterpulsation (eecp), on patients who have had fontan surgery for treatment of complex congenital heart disease. eligible patient volunteers will undergo a series of biophysical measurements at rest including echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement using an inert gas rebreathing method (innocor), and measurements of biomarkers of endothelial function (et-1, nox). patients will then undergo 1 hour of treatment with eecp, during which additional echocardiographic assessment of ventricular function and pulmonary blood flow/cardiac output measurements will be performed at multiple levels of leg compression. subjects will be assessed periodically for adverse effects and discomfort during the eecp treatment. at the completion of treatment, patients will be allowed 30 minutes to rest before undergoing one more echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement, and measurements of biomarkers of endothelial function (et-1, nox). measurements made during and after treatment will be compared to baseline measurements.

Eligibility criteria:
inclusion criteria: * individuals with fontan physiology being seen in the boston children's hospital cardiology clinic for outpatient care. exclusion criteria: * current pregnancy * decompensated heart failure/pulmonary edema * severe aortic insufficiency * active tachyarrhythmias * frequent atrial or ventricular ectopy * symptomatic peripheral vascular disease * thrombophlebitis or history of deep vein thrombosis or stasis ulcer * aortic aneurysm * uncontrolled hypertension (systolic blood pressure \>180 mmhg or diastolic blood pressure\>110 mmhg) * systolic blood pressure \<90 mmhg * active femoral site bleeding or hematoma

Keywords: fontan
biomarkers for human heart failure

Conditions: CHF

Summary: the purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or stemi (st-segment elevation myocardial infarction)/nstemi (non-st-segment elevation myocardial infarction), as well as history reviews.

schematic design of the study: single blood draw, one random urine and 24-hr urine collection from hospitalized patients with chronic/acute heart failure and/or stemi-nstemi. if there should be a subsequent hospitalization,another collection of a 45 ml blood sample, random urine and one 24-hour urine collection may be completed if indicated at initial hospitalization. aims: the purpose of this study is to attempt to establish the various ranges of proteins that can be assayed from the plasma and urine of patients with all classes of heart failure and mi (myocardial infarction). follow-up hospitalizations may result in another 45 ml blood draw, random urine and 24-hr. urine collection to evaluate the outcome of the heart failure treatment used with the previous hospitalization, if indicated in consent. a history review will be necessary as well.

Eligibility criteria:
inclusion criteria: • diagnosis of acute decompensated heart failure exclusion criteria: • hemoglobin less than 10, active cancer, or amyloidosis patient with dialysis
biomarkers predicting infectivity in an experimental human influenza model

Conditions: Influenza A

Summary: this study aims to test the hypothesis that gene transcriptional changes occur within 24 hours of virus exposure in the blood and nasal mucosa, and to identify early biomarker signatures that are predictive of higher viral shedding at the peak of disease

this study will systematically investigate the early pre-symptomatic period following exposure to influenza in humans. the data obtained will be essential for further understanding of the natural history of human antiviral responses, and will allow us to identify a panel of biomarkers that can predict which individuals will go on to more severe symptoms and higher viral shedding, so that treatments and other interventions can be made at an early stage.

Eligibility criteria:
inclusion criteria: * healthy persons aged 18 to 55 years, able to give informed consent exclusion criteria: * chronic respiratory disease (asthma, chronic obstructive pulmonary disease, rhinitis, sinusitis) in adulthood * inhaled bronchodilator or steroid use within the last 12 months * use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 6 months * acute upper respiratory infection or sinusitis in the past 6 weeks * smoking in the past 6 months or \>5 pack-year lifetime history * subjects with allergic symptoms present at baseline * clinically relevant abnormality on chest x-ray * those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (\>65 years), immunosuppressed persons, or those with chronic respiratory disease * subjects with known or suspected immune deficiency * receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge * known immunoglobulin a deficiency, immotile cilia syndrome, or kartagener's syndrome * history of frequent nose bleeds * any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study * pregnant or breastfeeding women * positive urine drug screen * detectable baseline haemagglutination inhibition titres against influenza challenge strains * history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine, or with life-threatening reactions to previous influenza vaccinations all women of childbearing age will have a pregnancy test performed prior to virus inoculation to exclude pregnancy and be required to use contraception throughout the study.
asymptomatic covid-19 trial

Conditions: SARS-CoV-2 Infection

Summary: the coronavirus disease-2019 (covid-19) is spreading throughout the united states. while there are no known therapies to treat those who have become sick, there have been some reports that a medication currently used to treat rheumatoid arthritis, lupus, and malaria (hydroxychloroquine sulfate, also known as plaquenil) may help to lessen the chance or severity of illness, especially if combined with a medicine that treats other kinds of infections (azithromycin, also known as zithromax or zmax or zpak). there are some people who test positive for the virus but who are otherwise not ill. current standard of care is to advise these people to self-monitor but no treatment is offered. it is not known how many of these individuals will remain symptom free, and how many will become sick or how severe those symptoms will be. this study will randomize those people who do not have symptoms into one of three treatment plans 1) hydroxycholoquine and azithromycin, or 2) no active medication (placebo). all participants will be followed for 2 months. the study will determine if there is any benefit to those who are asymptomatic to taking taking hydroxychloroquine sulfate in combination with azithromycin, or if there is no benefit from taking these medications.

participants will be randomized into one of two treatment plans 1. hydroxycholoquine sulfate in combination with azithromycin hydroxycholorquine as above, plus azithromycine: 500 mg po for day 1and then 250 mg qd for 4 days 2. no active medication (placebo) all participants will be followed for 2 months. the primary aim is to determine if there is any benefit (reduced likelihood for development of fever and other symptoms of covid-19 ) to taking only hydroxychloroquine sulfate, or to taking hydroxychloroquine sulfate in combination with azithromycin, or if there is no benefit to taking these medications for this population.

Eligibility criteria:
inclusion criteria: 1. documented sars-cov-2 infection by qpcr assay without symptoms consistent with covid-19 within 1 week of enrollment 2. age ≥20 exclusion criteria: 1. retinal eye disease 2. known glucose-6 phosphate dehydrogenase (g-6-pd) deficiency 3. known chronic kidney disease, stage 4 or 5 or receiving dialysis 4. current use of: * class 3 aad - amiodarone, dronaderone, dofetilide, sotalol) * class 1a aad (procainamide, quinidine, disopyramide) * flecainide * chlorpromazine * cilostazol (pletal) * donepezil (aricept) * droperidol * fluconazole * methadone * ondansetron(zofran) * thioridazine * macrolides (clarithromycin, erythromycin) * fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) 5. pregnancy or women who are breast feeding 6. inability to tolerate oral medications 7. allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate 8. allergy to adhesives 9. qtc interval \> 450 msec for men and women 10. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 11. non-english-speaking
ibs-c questionnaire study

Conditions: Irritable Bowel Syndrome With Constipation; Functional Constipation

Summary: the study is a multi-centre, observational study which enrolls 150 ibs-c patients and 150 non-ibs-c patients in china.

the potential study subject will be identified by the investigators by face-to-face visit, and there will be only 1 visit in this study. every patient will complete both rome iv and the simplified diagnosis tool during the visit, and in the same day. the study will collect results of the rome iv and the simplified diagnosis tool. sensitivity and specificity of simplified diagnosis methodology compared with rome iv will be analysed after all the data has been collected.

Eligibility criteria:
inclusion criteria: group 1 (ibs-c) * ≥18 years old * decrease of frequency of bowel movement (\<3 time per week), change of stool consistency (stool that is hard and difficult to pass, bristol types 1 to 3), or other 'constipation symptoms' judged by investigators. * with abdominal symptoms such as abdominal pain, bloating, and abdominal discomfort, or other 'constipation symptoms' judged by investigators. * result of rome vi marked as 'ibs-c'. group 2 (non-ibs-c) * ≥18 years old * decrease of frequency of bowel movement (\<3 time per week), change of stool consistency (stool that is hard and difficult to pass, bristol types 1 to 3), or other 'constipation symptoms' judged by investigators. * with abdominal symptoms such as abdominal pain, bloating, and abdominal discomfort, or other 'constipation symptoms' judged by investigators. * result of rome vi marked as 'non ibs-c'. exclusion criteria: * individuals with a cognitive condition and unable to finish the questionnaire. * individuals have an acute or chronic non-gi condition that can be associated with constipation; e.g., central nervous system cause (parkinson's disease, spinal cord injury, and multiple sclerosis), pseudo-obstruction, colonic inertia, megacolon, megarectum, bowel obstruction, descending perineum syndrome, solitary rectal ulcer syndrome, systemic sclerosis. * individuals who had been diagnosed with the following organic health problems likely to affect gi symptoms: * inflammatory bowel disease (crohn's disease or ulcerative colitis) * cancer anywhere in the gi tract or current infection of the gi tract. * pelvic floor dysfunction. (i.e., disease that is not adequately treated or stable with therapy.) * any history of colon surgeries. * individuals who participate in any interventional study currently. * not suitable for the study judged by investigators.

Keywords: ibs-c; functional constipation; diagnosis, questionnaire